Outcome Measures for Clinical Trials in Sepsis: Introduction John C. Marshall OriginalPaper Pages: 11 - 12
Defining the Biologic Objectives of Mediator-Directed Therapy: Overview John C. Marshall OriginalPaper Pages: 13 - 13
Outcome Measures: Methodologic Principles Gordon H. GuyattMaureen O. Meade OriginalPaper Pages: 21 - 25
Systematic Review of Outcome Measures in Randomized Trials of Mediator-Directed Therapies in Sepsis Maureen O. MeadeDavid CreeryJohn C. Marshall OriginalPaper Pages: 27 - 33
The Measurement of Organ Dysfunction/Failure as an ICU Outcome John C. MarshallGordon BernardJean-Louis Vincent OriginalPaper Pages: 41 - 41
How to Assess Organ Dysfunction in the Intensive Care Unit? The Logistic Organ Dysfunction (LOD) System Jean-Roger Le GallJanelle KlarStanley Lemeshow OriginalPaper Pages: 45 - 47
Organ Dysfunction as an Outcome Measure: The Sofa Score Jean-Louis Vincent OriginalPaper Pages: 53 - 54
The Microbial Consequences of Antimediator Therapy for Sepsis Steven M. OpalAlan S. Cross OriginalPaper Pages: 59 - 64
Measuring the Biological Efficacy of Mediator-Directed Therapy Michael R. Pinsky OriginalPaper Pages: 65 - 67
Fda Perspective on Study Design for Therapies for Severe Sepsis William SchwietermanRosemary Roberts OriginalPaper Pages: 69 - 69
Regulatory Factors in the EU–Possible Considerations for the Drug Development Process Mair Powell OriginalPaper Pages: 71 - 73
